-
1
-
-
85048877561
-
-
Accessed 12 Mar 2014
-
World Health Organization. NCD mortality and morbidity. http://www.who.int/gho/ncd/mortality_morbidity/en. Accessed 12 Mar 2014.
-
NCD mortality and morbidity
-
-
-
2
-
-
84867061549
-
Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits
-
COI: 1:CAS:528:DC%2BC3sXnsFejtrY%3D, PID: 22893203
-
Rothwell PM. Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. Recent Results Cancer Res. 2013;191:121–42.
-
(2013)
Recent Results Cancer Res.
, vol.191
, pp. 121-142
-
-
Rothwell, P.M.1
-
3
-
-
84860386459
-
The role of aspirin in cancer prevention
-
COI: 1:CAS:528:DC%2BC38XmtlGgurc%3D, PID: 22473097
-
Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9:259–67.
-
(2012)
Nat Rev Clin Oncol.
, vol.9
, pp. 259-267
-
-
Thun, M.J.1
Jacobs, E.J.2
Patrono, C.3
-
4
-
-
84876900933
-
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts
-
COI: 1:CAS:528:DC%2BC3sXpsFCmu7Y%3D, PID: 23408351
-
Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.
-
(2013)
Gut.
, vol.62
, pp. 812-823
-
-
Vasen, H.F.1
Blanco, I.2
Aktan-Collan, K.3
-
5
-
-
65849268320
-
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
-
PID: 19482214
-
Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.
-
(2009)
Lancet.
, vol.373
, pp. 1849-1860
-
-
Baigent, C.1
Blackwell, L.2
Collins, R.3
-
6
-
-
79957954493
-
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin
-
COI: 1:CAS:528:DC%2BC3MXntVersL0%3D, PID: 21481826
-
Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796–801.
-
(2011)
Am J Cardiol.
, vol.107
, pp. 1796-1801
-
-
Bartolucci, A.A.1
Tendera, M.2
Howard, G.3
-
7
-
-
79959345305
-
Effect of aspirin on mortality in the primary prevention of cardiovascular disease
-
COI: 1:CAS:528:DC%2BC3MXnslSiu7o%3D, PID: 21592450
-
Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–9.
-
(2011)
Am J Med.
, vol.124
, pp. 621-629
-
-
Raju, N.1
Sobieraj-Teague, M.2
Hirsh, J.3
-
8
-
-
84857376799
-
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials
-
COI: 1:CAS:528:DC%2BC38XktFequ78%3D, PID: 22231610
-
Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209–16.
-
(2012)
Arch Intern Med.
, vol.172
, pp. 209-216
-
-
Seshasai, S.R.1
Wijesuriya, S.2
Sivakumaran, R.3
-
9
-
-
79953246984
-
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis
-
COI: 1:CAS:528:DC%2BC3MXltVWlu78%3D, PID: 21453547
-
Butalia S, Leung A, Ghali W, et al. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011;10:25.
-
(2011)
Cardiovasc Diabetol.
, vol.10
, pp. 25
-
-
Butalia, S.1
Leung, A.2
Ghali, W.3
-
10
-
-
71749105108
-
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
-
PID: 19897665
-
De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.
-
(2009)
BMJ.
, vol.339
, pp. b4531
-
-
De Berardis, G.1
Sacco, M.2
Strippoli, G.F.3
-
11
-
-
78651266855
-
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis
-
PID: 21191260
-
Stavrakis S, Stoner JA, Azar M, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011;341:1–9.
-
(2011)
Am J Med Sci.
, vol.341
, pp. 1-9
-
-
Stavrakis, S.1
Stoner, J.A.2
Azar, M.3
-
12
-
-
77952685474
-
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis
-
COI: 1:CAS:528:DC%2BC3cXmt12ltrY%3D, PID: 20429671
-
Younis N, Williams S, Ammori B, et al. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother. 2010;11:1459–66.
-
(2010)
Expert Opin Pharmacother.
, vol.11
, pp. 1459-1466
-
-
Younis, N.1
Williams, S.2
Ammori, B.3
-
13
-
-
74449086639
-
Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis
-
COI: 1:CAS:528:DC%2BC3cXhtVGgu7g%3D, PID: 19853947
-
Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211–8.
-
(2010)
Diabetes Res Clin Pract.
, vol.87
, pp. 211-218
-
-
Zhang, C.1
Sun, A.2
Zhang, P.3
-
14
-
-
0026775578
-
Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14
-
Kassoff A, Buzney SM, McMeel J, et al. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268:1292–300.
-
(1992)
JAMA.
, vol.268
, pp. 1292-1300
-
-
Kassoff, A.1
Buzney, S.M.2
McMeel, J.3
-
15
-
-
55949127696
-
The Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
-
PID: 18927173
-
Belch J, MacCuish A, Campbell I, et al. The Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
-
(2008)
BMJ.
, vol.337
, pp. a1840
-
-
Belch, J.1
MacCuish, A.2
Campbell, I.3
-
16
-
-
0035852471
-
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project
-
PID: 11197445
-
de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89–95.
-
(2001)
Lancet.
, vol.357
, pp. 89-95
-
-
de Gaetano, G.1
-
17
-
-
77649198148
-
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial
-
COI: 1:CAS:528:DC%2BC3cXivFKrtrc%3D, PID: 20197530
-
Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–8.
-
(2010)
JAMA.
, vol.303
, pp. 841-848
-
-
Fowkes, F.G.1
Price, J.F.2
Stewart, M.C.3
-
18
-
-
0032513878
-
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
-
COI: 1:CAS:528:DyaK1cXksV2qtrY%3D, PID: 9635947
-
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.
-
(1998)
Lancet.
, vol.351
, pp. 1755-1762
-
-
Hansson, L.1
Zanchetti, A.2
Carruthers, S.G.3
-
19
-
-
56149113603
-
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial
-
COI: 1:CAS:528:DC%2BD1cXhtlOrtLnM, PID: 18997198
-
Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41.
-
(2008)
JAMA.
, vol.300
, pp. 2134-2141
-
-
Ogawa, H.1
Nakayama, M.2
Morimoto, T.3
-
20
-
-
0023845856
-
Randomised trial of prophylactic daily aspirin in British male doctors
-
COI: 1:STN:280:DyaL1c7ltVCjsA%3D%3D
-
Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313–6.
-
(1988)
Br Med J (Clin Res Ed).
, vol.296
, pp. 313-316
-
-
Peto, R.1
Gray, R.2
Collins, R.3
-
21
-
-
15744378579
-
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women
-
COI: 1:CAS:528:DC%2BD2MXislCjs7Y%3D, PID: 15753114
-
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304.
-
(2005)
N Engl J Med.
, vol.352
, pp. 1293-1304
-
-
Ridker, P.M.1
Cook, N.R.2
Lee, I.M.3
-
22
-
-
0024406369
-
Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group
-
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med. 1989;321:129–35.
-
(1989)
N Engl J Med.
, vol.321
, pp. 129-135
-
-
Steering Committee of the Physicians’ Health Study Research Group1
-
23
-
-
0032562005
-
Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework
-
The Medical Research Council’s General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet. 1998;351:233–41.
-
(1998)
Lancet.
, vol.351
, pp. 233-241
-
-
The Medical Research Council’s General Practice Research Framework1
-
24
-
-
82955187871
-
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects
-
COI: 1:CAS:528:DC%2BC3MXhsFygu77K, PID: 22090661
-
Dorresteijn JAN, Visseren FLJ, Ridker PM, et al. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J. 2011;32:2962–9.
-
(2011)
Eur Heart J.
, vol.32
, pp. 2962-2969
-
-
Dorresteijn, J.A.N.1
Visseren, F.L.J.2
Ridker, P.M.3
-
25
-
-
77956525281
-
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial
-
COI: 1:CAS:528:DC%2BC3cXhtlWjt7jF, PID: 20828648
-
Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56:956–65.
-
(2010)
J Am Coll Cardiol.
, vol.56
, pp. 956-965
-
-
Jardine, M.J.1
Ninomiya, T.2
Perkovic, V.3
-
26
-
-
79960722525
-
Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women’s Health Study
-
PID: 21673005
-
Kurth T, Diener HC, Buring JE. Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women’s Health Study. Cephalalgia. 2011;31:1106–15.
-
(2011)
Cephalalgia.
, vol.31
, pp. 1106-1115
-
-
Kurth, T.1
Diener, H.C.2
Buring, J.E.3
-
27
-
-
84861602573
-
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial
-
COI: 1:CAS:528:DC%2BC38Xpsl2rsrs%3D, PID: 22447019
-
Soejima H, Ogawa H, Morimoto T, et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circ J. 2012;76:1526–32.
-
(2012)
Circ J.
, vol.76
, pp. 1526-1532
-
-
Soejima, H.1
Ogawa, H.2
Morimoto, T.3
-
28
-
-
80755153633
-
Effects of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis
-
PID: 21647746
-
Simpson SH, Gamble JM, Mereu L, et al. Effects of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011;26:1336–44.
-
(2011)
J Gen Intern Med.
, vol.26
, pp. 1336-1344
-
-
Simpson, S.H.1
Gamble, J.M.2
Mereu, L.3
-
29
-
-
84864406576
-
Aspirin for the primary prevention of cardiovascular diseases
-
PID: 22669555
-
Tagliabue L, Dipaola F, Perego F, et al. Aspirin for the primary prevention of cardiovascular diseases. Intern Emerg Med. 2012;7:375–9.
-
(2012)
Intern Emerg Med.
, vol.7
, pp. 375-379
-
-
Tagliabue, L.1
Dipaola, F.2
Perego, F.3
-
30
-
-
79960200973
-
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials
-
PID: 21742097
-
Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(115–24):e2.
-
(2011)
Am Heart J.
, vol.162
, Issue.115-24
, pp. e2
-
-
Berger, J.S.1
Lala, A.2
Krantz, M.J.3
-
31
-
-
30944467297
-
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials
-
COI: 1:CAS:528:DC%2BD28XlsVSjsA%3D%3D, PID: 16418466, (Erratum in: JAMA. 2006;295:2002)
-
Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–13 (Erratum in: JAMA. 2006;295:2002).
-
(2006)
JAMA
, vol.295
, pp. 306-313
-
-
Berger, J.S.1
Roncaglioni, M.C.2
Avanzini, F.3
-
32
-
-
78650825618
-
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
-
COI: 1:CAS:528:DC%2BC3MXms1Wk, PID: 21144578
-
Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41.
-
(2011)
Lancet.
, vol.377
, pp. 31-41
-
-
Rothwell, P.M.1
Fowkes, F.G.2
Belch, J.F.3
-
33
-
-
84863399038
-
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
-
COI: 1:CAS:528:DC%2BC38XktlGku7c%3D, PID: 22440947
-
Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601.
-
(2012)
Lancet.
, vol.379
, pp. 1591-1601
-
-
Rothwell, P.M.1
Wilson, M.2
Price, J.F.3
-
34
-
-
84863412124
-
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
-
COI: 1:CAS:528:DC%2BC38XktlGkurw%3D, PID: 22440946
-
Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–12.
-
(2012)
Lancet.
, vol.379
, pp. 1602-1612
-
-
Rothwell, P.M.1
Price, J.F.2
Fowkes, F.G.3
-
35
-
-
84861722871
-
Aspirin and cancer risk: a quantitative review to 2011
-
COI: 1:STN:280:DC%2BC38rmsFWhtQ%3D%3D, PID: 22517822
-
Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403–15.
-
(2012)
Ann Oncol.
, vol.23
, pp. 1403-1415
-
-
Bosetti, C.1
Rosato, V.2
Gallus, S.3
-
36
-
-
84861529382
-
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials
-
COI: 1:CAS:528:DC%2BC38XlvVSgtbk%3D, PID: 22513195
-
Mills EJ, Wu P, Alberton M, et al. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med. 2012;125:560–7.
-
(2012)
Am J Med.
, vol.125
, pp. 560-567
-
-
Mills, E.J.1
Wu, P.2
Alberton, M.3
-
37
-
-
84874372330
-
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies
-
COI: 1:CAS:528:DC%2BC3sXjslyksb8%3D, PID: 23451245
-
Ye X, Fu J, Yang Y, et al. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8:e57578.
-
(2013)
PLoS One.
, vol.8
, pp. e57578
-
-
Ye, X.1
Fu, J.2
Yang, Y.3
-
38
-
-
60749128400
-
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials
-
COI: 1:CAS:528:DC%2BD1MXisVSksr8%3D, PID: 19211452
-
Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256–66.
-
(2009)
J Natl Cancer Inst.
, vol.101
, pp. 256-266
-
-
Cole, B.F.1
Logan, R.F.2
Halabi, S.3
-
39
-
-
72949123788
-
The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials
-
COI: 1:STN:280:DC%2BD1Mnpt12kuw%3D%3D, PID: 19055515
-
Gao F, Liao C, Liu L, et al. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Colorectal Dis. 2009;11:893–901.
-
(2009)
Colorectal Dis.
, vol.11
, pp. 893-901
-
-
Gao, F.1
Liao, C.2
Liu, L.3
-
40
-
-
84860467522
-
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials
-
COI: 1:CAS:528:DC%2BC38Xmslyhsbs%3D, PID: 22440112
-
Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–27.
-
(2012)
Lancet Oncol.
, vol.13
, pp. 518-527
-
-
Algra, A.M.1
Rothwell, P.M.2
-
41
-
-
79955832527
-
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis
-
COI: 1:CAS:528:DC%2BC3MXnslektL8%3D, PID: 21543343
-
Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4:655–65.
-
(2011)
Cancer Prev Res (Phila).
, vol.4
, pp. 655-665
-
-
Burn, J.1
Bishop, D.T.2
Chapman, P.D.3
-
42
-
-
83955161674
-
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
-
PID: 22036019
-
Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–7.
-
(2011)
Lancet.
, vol.378
, pp. 2081-2087
-
-
Burn, J.1
Gerdes, A.M.2
Macrae, F.3
-
43
-
-
70350101185
-
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence—data from a randomized clinical trial
-
COI: 1:CAS:528:DC%2BD1MXht1OiurnJ, PID: 19755647
-
Barry EL, Sansbury LB, Grau MV, et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence—data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2009;18:2726–33.
-
(2009)
Cancer Epidemiol Biomarkers Prev.
, vol.18
, pp. 2726-2733
-
-
Barry, E.L.1
Sansbury, L.B.2
Grau, M.V.3
-
44
-
-
57749107623
-
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome
-
COI: 1:CAS:528:DC%2BD1cXhsV2ktrvM, PID: 19073976
-
Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359:2567–78.
-
(2008)
N Engl J Med.
, vol.359
, pp. 2567-2578
-
-
Burn, J.1
Bishop, D.T.2
Mecklin, J.P.3
-
45
-
-
0026355123
-
The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results
-
COI: 1:STN:280:DyaK387kvVClsA%3D%3D, PID: 1783914
-
Farrell B, Godwin J, Richards S, et al. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–54.
-
(1991)
J Neurol Neurosurg Psychiatry.
, vol.54
, pp. 1044-1054
-
-
Farrell, B.1
Godwin, J.2
Richards, S.3
-
46
-
-
84878241212
-
Aspirin for primary prevention of CVD: are the right people using it?
-
PID: 23000660
-
Vanwormer JJ, Greenlee RT, McBride PE, et al. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract. 2012;61:525–33.
-
(2012)
J Fam Pract.
, vol.61
, pp. 525-533
-
-
Vanwormer, J.J.1
Greenlee, R.T.2
McBride, P.E.3
-
47
-
-
80054863908
-
A national survey on aspirin patterns of use and persistence in community outpatients in Italy
-
PID: 21450601
-
Filippi A, Bianchi C, Parazzini F, et al. A national survey on aspirin patterns of use and persistence in community outpatients in Italy. Eur J Cardiovasc Prev Rehabil. 2011;18:695–703.
-
(2011)
Eur J Cardiovasc Prev Rehabil.
, vol.18
, pp. 695-703
-
-
Filippi, A.1
Bianchi, C.2
Parazzini, F.3
-
48
-
-
78650132509
-
Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis
-
PID: 21146684
-
Sanchez DR, Diez Roux AV, Michos ED, et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol. 2011;107:41–6.
-
(2011)
Am J Cardiol
, vol.107
, pp. 41-46
-
-
Sanchez, D.R.1
Diez Roux, A.V.2
Michos, E.D.3
-
49
-
-
84865677850
-
Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients
-
PID: 22748400
-
Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(882–87):e1.
-
(2012)
Am J Med.
, vol.125
, Issue.882-87
, pp. e1
-
-
Naderi, S.H.1
Bestwick, J.P.2
Wald, D.S.3
-
50
-
-
84863704038
-
Aspirin in the primary prevention of cardiovascular disease in the Women’s Health Study: effect of noncompliance
-
COI: 1:CAS:528:DC%2BC38XpsVKltL4%3D, PID: 22699516
-
Cook NR, Cole SR, Buring JE. Aspirin in the primary prevention of cardiovascular disease in the Women’s Health Study: effect of noncompliance. Eur J Epidemiol. 2012;27:431–8.
-
(2012)
Eur J Epidemiol.
, vol.27
, pp. 431-438
-
-
Cook, N.R.1
Cole, S.R.2
Buring, J.E.3
-
51
-
-
84871995815
-
Standards of medical care in diabetes—2013
-
American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–66.
-
(2013)
Diabetes Care.
, vol.36
, pp. S11-S66
-
-
American Diabetes Association1
-
52
-
-
84862119222
-
The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
-
Perk J, De Backer G, Gohlke H, European Guidelines on cardiovascular disease prevention in clinical practice (version, 2012), et al. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;2012(33):1635–701.
-
(2012)
Eur Heart J.
, vol.2012
, Issue.33
, pp. 1635-1701
-
-
Perk, J.1
De Backer, G.2
Gohlke, H.3
-
53
-
-
84856794168
-
Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
-
COI: 1:CAS:528:DC%2BC38XnsVOrtb0%3D, PID: 22315274
-
Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e637S–68S.
-
(2012)
Chest.
, vol.141
, pp. e637S-e668S
-
-
Vandvik, P.O.1
Lincoff, A.M.2
Gore, J.M.3
-
54
-
-
79251601596
-
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association
-
PID: 21127304
-
Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517–84.
-
(2011)
Stroke.
, vol.42
, pp. 517-584
-
-
Goldstein, L.B.1
Bushnell, C.D.2
Adams, R.J.3
-
55
-
-
63849141400
-
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement
-
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.
-
(2009)
Ann Intern Med.
, vol.150
, pp. 396-404
-
-
US Preventive Services Task Force1
-
56
-
-
58049193590
-
Diabetes and aspirin: beware of underpowered negative trials
-
PID: 19088728
-
Farkouh ME, Fuster V. Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med. 2009;6:1.
-
(2009)
Nat Clin Pract Cardiovasc Med.
, vol.6
, pp. 1
-
-
Farkouh, M.E.1
Fuster, V.2
-
57
-
-
84865451602
-
Diabetes: does aspirin increase the risk of major bleeds?
-
COI: 1:CAS:528:DC%2BC38Xht1GjtrvI, PID: 22847167
-
Patrono C. Diabetes: does aspirin increase the risk of major bleeds? Nat Rev Cardiol. 2012;9:495–6.
-
(2012)
Nat Rev Cardiol.
, vol.9
, pp. 495-496
-
-
Patrono, C.1
-
58
-
-
84863430537
-
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
-
COI: 1:CAS:528:DC%2BC38Xht1ChtbfJ, PID: 22471290
-
Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10:1220–30.
-
(2012)
J Thromb Haemost.
, vol.10
, pp. 1220-1230
-
-
Rocca, B.1
Santilli, F.2
Pitocco, D.3
-
59
-
-
84879958722
-
The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study
-
PID: 23797426
-
Rosiak M, Postula M, Kaplon-Cieslicka A, et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiol Pol. 2013;71:552–7.
-
(2013)
Kardiol Pol.
, vol.71
, pp. 552-557
-
-
Rosiak, M.1
Postula, M.2
Kaplon-Cieslicka, A.3
-
60
-
-
78650215449
-
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
-
COI: 1:CAS:528:DC%2BC3cXhsVGitbfF, PID: 20970847
-
Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–50.
-
(2010)
Lancet.
, vol.376
, pp. 1741-1750
-
-
Rothwell, P.M.1
Wilson, M.2
Elwin, C.E.3
-
61
-
-
23944436934
-
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer
-
COI: 1:CAS:528:DC%2BD2MXptVClsro%3D, PID: 16118381
-
Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914–23.
-
(2005)
JAMA.
, vol.294
, pp. 914-923
-
-
Chan, A.T.1
Giovannucci, E.L.2
Meyerhardt, J.A.3
-
62
-
-
84880278340
-
Alternate-day low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial
-
PID: 23856681
-
Cook NR, Lee IM, Zhang SM, et al. Alternate-day low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77–85.
-
(2013)
Ann Intern Med.
, vol.159
, pp. 77-85
-
-
Cook, N.R.1
Lee, I.M.2
Zhang, S.M.3
-
64
-
-
77951737376
-
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention
-
COI: 1:CAS:528:DC%2BC3cXnvFKhsrw%3D, PID: 20427397
-
Benamouzig R, Uzzan B, Martin A, et al. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut. 2010;59:622–9.
-
(2010)
Gut.
, vol.59
, pp. 622-629
-
-
Benamouzig, R.1
Uzzan, B.2
Martin, A.3
-
65
-
-
0034946873
-
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs
-
COI: 1:CAS:528:DC%2BD3MXkvVarsrg%3D, PID: 11435450
-
Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7–13.
-
(2001)
J Clin Invest.
, vol.108
, pp. 7-13
-
-
Patrono, C.1
Patrignani, P.2
Garcia Rodriguez, L.A.3
-
66
-
-
84855556537
-
Aspirin in the chemoprevention of colorectal neoplasia: an overview
-
COI: 1:CAS:528:DC%2BC38XjvValtb0%3D, PID: 22084361
-
Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164–78.
-
(2012)
Cancer Prev Res (Phila).
, vol.5
, pp. 164-178
-
-
Chan, A.T.1
Arber, N.2
Burn, J.3
-
67
-
-
33748316476
-
Review article: gastrointestinal bleeding with low-dose aspirin—what’s the risk?
-
COI: 1:CAS:528:DC%2BD28Xht1enu73J, PID: 16948802
-
Laine L. Review article: gastrointestinal bleeding with low-dose aspirin—what’s the risk? Aliment Pharmacol Ther. 2006;24:897–908.
-
(2006)
Aliment Pharmacol Ther.
, vol.24
, pp. 897-908
-
-
Laine, L.1
-
68
-
-
28244459634
-
Low-dose aspirin for the prevention of atherothrombosis
-
COI: 1:CAS:528:DC%2BD2MXht1OmsbnM, PID: 16319386
-
Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83.
-
(2005)
N Engl J Med
, vol.353
, pp. 2373-2383
-
-
Patrono, C.1
Garcia Rodriguez, L.A.2
Landolfi, R.3
-
69
-
-
77956417776
-
Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin
-
COI: 1:CAS:528:DC%2BC3cXht1GjurnM, PID: 20659284
-
Fletcher EH, Johnston DE, Fisher CR, et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32:831–9.
-
(2010)
Aliment Pharmacol Ther.
, vol.32
, pp. 831-839
-
-
Fletcher, E.H.1
Johnston, D.E.2
Fisher, C.R.3
-
70
-
-
84874088293
-
Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users
-
COI: 1:CAS:528:DC%2BC3sXislyrsb4%3D, PID: 23333655
-
Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–35.
-
(2013)
Gastroenterology.
, vol.144
, pp. 528-535
-
-
Chan, F.K.1
Ching, J.Y.2
Suen, B.Y.3
-
71
-
-
84891918487
-
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials
-
PID: 24339983
-
Sutcliffe P, Connock M, Gurung T, et al. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One. 2013;8:e81970.
-
(2013)
PLoS One.
, vol.8
, pp. e81970
-
-
Sutcliffe, P.1
Connock, M.2
Gurung, T.3
-
72
-
-
84857608400
-
The role of low-dose aspirin in the prevention of colorectal cancer
-
COI: 1:CAS:528:DC%2BC38XivFOnurY%3D, PID: 22313430
-
Avivi D, Moshkowitz M, Detering E, et al. The role of low-dose aspirin in the prevention of colorectal cancer. Expert Opin Ther Targets. 2012;16:S51–62.
-
(2012)
Expert Opin Ther Targets.
, vol.16
, pp. S51-S62
-
-
Avivi, D.1
Moshkowitz, M.2
Detering, E.3
-
73
-
-
77957298700
-
The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk
-
COI: 1:CAS:528:DC%2BC3cXhsVahtbbK, PID: 20666569
-
Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10:281–8.
-
(2010)
Am J Cardiovasc Drugs.
, vol.10
, pp. 281-288
-
-
Pratt, S.1
Thompson, V.J.2
Elkin, E.P.3
-
74
-
-
3442880051
-
Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association
-
PID: 15198946
-
Eyre H, Kahn R, Robertson RM, et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation. 2004;109:3244–55.
-
(2004)
Circulation.
, vol.109
, pp. 3244-3255
-
-
Eyre, H.1
Kahn, R.2
Robertson, R.M.3
|